Emergence of Bruton's tyrosine kinase‐negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. (5th July 2017)

• Record Type: Journal Article
• Authors: Glavey, Siobhan; Quinn, John; McCloy, Mary; Sargent, Jeremy; McCartney, Yvonne; Catherwood, Mark; Marafioti, Teresa; Leader, Mary; Murphy, Philip; Thornton, Patrick
• Is Part Of: European journal of haematology. Volume 99:Number 4(2017)
• Page Start: 378
• Page End: 380
• Publication Date: 2017-07-05
• Subjects: chronic lymphocytic leukaemia -- Hodgkin lymphoma; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12911
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Chronic lymphocytic leukaemia (CLL) is a chronic B‐cell lympho‐proliferative disorder in which lymphomatous transformations occur in 5%‐15% of patients. Histologically these cases resemble diffuse large B‐cell lymphoma, or Richter's transformation, in over 80% of cases. Rare cases of transformation to Hodgkin lymphoma (HL) have been reported in the literature with an estimated prevalence of 0.4%. We report a case of a 67‐year‐old female with CLL treated with the novel Bruton's tyrosine kinase (Btk) inhibitor, ibrutinib, who subsequently presented with intractable fevers. Bone marrow trephine, and lymph node biopsy revealed classical HL with negative immuno‐histochemistry for Btk in HL cells, on a backdrop of CLL. The patient commenced treatment with Adriamycin, Vinblastine and Dacarbazine (AVD), which resulted in an excellent response. Hodgkin transformation of CLL is rare with a single retrospective study of 4121 CLL patients reporting only 18 cases. Btk expression in HL cells is recently recognised in classical HL; however, the majority of HLs are Btk negative. Given that Btk inhibitors have recently been shown to induce genomic instability in B cells, in the context of their widespread use, such emerging cases are increasingly relevant.